



## Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March

REDWOOD CITY, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences.

- Management will deliver a company presentation at the 38<sup>th</sup> Cowen & Company Healthcare Conference on Tuesday, March 12<sup>th</sup> at 10 a.m. ET taking place in Boston, Massachusetts.
- Management will deliver a company presentation at Barclays Global Healthcare Conference on Wednesday, March 13<sup>th</sup> at 8:00 a.m. ET taking place in Miami, Florida.

The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at <http://investors.coherus.com>.

### About Coherus BioSciences, Inc.

Coherus BioSciences is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus BioSciences is positioned as a leader in the global biosimilar marketplace. Coherus BioSciences commercializes Udenyca™ (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for Udenyca™ in the European Union. Coherus BioSciences is advancing two late-stage clinical products towards commercialization, CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), and developing a robust pipeline of future products in ophthalmology (including CHS-3351, a ranibizumab biosimilar, and CHS-2020, an aflibercept biosimilar), as well as CHS-131, a small molecule for nonalcoholic steatohepatitis (NASH) and multiple sclerosis. For additional information, please visit [www.coherus.com](http://www.coherus.com).

### CONTACT:

David S. Arrington  
VP, Investor Relations & Corporate Affairs  
Coherus BioSciences, Inc.  
[darrington@coherus.com](mailto:darrington@coherus.com)  
+1 (650) 395-0196



Source: Coherus BioSciences, Inc.